Testing of the Akt/PKB Inhibitor MK-2206 by the Pediatric Preclinical Testing Program

BACKGROUND: MK-2206 is a small molecule allosteric inhibitor of Akt/PKB that is undergoing clinical trials for treatment of cancer. PROCEDURES: MK-2206 was tested against the PPTP in vitro panel using a 96 hour exposure (1.0 nM-10 μM), and in vivo using thrice weekly dosing for a planned 4 weeks at...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gorlick, Richard, Maris, John M., Houghton, Peter J., Lock, Richard, Carol, Hernan, Kurmasheva, Raushan T., Kolb, E. Anders, Keir, Stephen T., Reynolds, C. Patrick, Kang, Min H., Billups, Catherine A., Smith, Malcolm A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3290691/
https://ncbi.nlm.nih.gov/pubmed/22102563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.23412
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak